

# Dyadic International Inc

21:15 13 Aug 2019

## Dyadic expands technology platform in 2Q through multiple collaborations, sub-licensing pacts

Dyadic International Inc (NASDAQ:DYAI) said Tuesday that its second quarter saw continued momentum with the expansion of its gene expression technology platform through multiple collaborations and sub-licensing agreements as it reported solid financial results for the period.

In a statement, Dyadic's Chief Executive Officer, Mark Emalfarb said: "I am pleased to report that we maintained our momentum in the second quarter by signing several agreements with highly experienced, value-added partners, including the Serum Institute of India. Serum is one of the world's largest vaccine manufacturers and our collaboration provides for the development and manufacture up to twelve antibodies and vaccines using Dyadic's C1 gene expression platform."

"We expect these relationships, along with those we signed in the first quarter and the recent agreement we signed earlier this week with a top tier pharmaceutical company, will further the development of our C1 technology platform and expand the breadth of potential commercial opportunities for human and animal health applications," he added.

READ: Dyadic extends R&D agreement with VTT Technical Research Centre of Finland

Emalfarb concluded: "We continue to make progress executing on our vision of creating more efficient and commercially cost-effective healthcare solutions for society globally. Based on the number of additional non-disclosure agreements we have signed year to date and our ongoing discussions with several pharma and biotech companies, we look forward to sharing additional new developments as the second half of the year unfolds."

Jupiter, Florida-based Dyadic leverages its proprietary C1 technology — an industrially proven fungal gene expression technology — to help bring biologic vaccines, enzymes, proteins, biosimilars, and drugs to market faster and at a lower cost.

Dyadic has patented its proprietary filamentous fungus, Myceliophthora thermophila, nicknamed C1 and the associated molecular tools used to engineer the C1 cells to express and manufacture large volumes of low-cost biologic products such as enzymes and proteins. The C1 fungus, is a living cell that has been bioengineered by Dyadic scientists for more than two decades.

### Financial highlights

For the quarter ended June 30, Dyadic's research and development revenue increased to \$391,000 compared to \$161,000 for the same period in the previous year.

However, the cost of R&D also increased to nearly \$322,000 compared to \$129,000 for the same period a year earlier. The company explained that the increases in revenue and R&D costs were linked to four ongoing research

**Price:** 5.83

**Market Cap:** \$158.65 m

### 1 Year Share Price Graph



### Share Information

**Code:** DYAI  
**Listing:** NASDAQ  
**52 week High:** 7.3  
**52 week Low:** 1.84  
**Sector:** Pharma & Biotech  
**Website:** www.dyadic.com

### Company Synopsis:

*Dyadic International, Inc. is a global biotechnology company focused on further improving and applying its proprietary C1 expression platform to help speed the development and lower the cost of biologic vaccines and drugs for animal and human health applications.*

[action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

collaborations during the quarter, compared to just two in the same period in the previous year.

Dyaadic's net loss for the quarter was roughly \$2.7 million, or \$0.10 per share, compared to a loss of \$1.6 million, or \$0.06 per share for the same period in the previous year.

As of June 30, the company's cash and cash equivalents totaled \$4.8 million compared to \$2.4 million on December 31, 2018. Meanwhile, the carrying value of investment grade securities, including accrued interest totaled \$34 million.

Contact Uttara Choudhury at [uttara@proactiveinvestors.com](mailto:uttara@proactiveinvestors.com)

Follow her on Twitter: [@UttaraProactive](https://twitter.com/UttaraProactive)

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

#### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Dyadic International Inc named herein, including the promotion by the Company of Dyadic International Inc in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).